In this article, we will list the 5 Overlooked Penny Stocks to Buy Right Now. Please visit 10 Overlooked Penny Stocks to Buy Right Now if you’d like to see an extended list and how we came up with the list of overlooked penny stocks to buy.

5. Opus Genetics, Inc. (NASDAQ:IRD)

Number of Hedge Fund Holders: 23

Upside Potential: 139.23%

Opus Genetics, Inc. (NASDAQ:IRD), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. A bullish new analyst call and a broadening gene therapy pipeline are boosting confidence in the stock’s outlook.

On June 23, 2026, RBC Capital initiated coverage of Opus Genetics, Inc. (NASDAQ:IRD) with an “Outperform” rating and a $10 price target. The analyst called the setup favorable amid limited competition, de-risked science, and what the firm described as recent FDA leniency. The note projected upside tied to the upcoming BEST1 data readout in September and four more clinical pipeline readouts expected in 2027.

That upside case follows a Research and Development Science Forum Opus Genetics, Inc. (NASDAQ:IRD) hosted on June 16, 2026, where management detailed three new programs entering clinical testing alongside recent LCA5 and BEST1 clinical data. Management also discussed the global IRD market opportunity, as well as its clinical development and execution strategies.

CEO George Magrath said Opus Genetics, Inc. (NASDAQ:IRD) holds first-mover advantage across multiple indications, backed by broad intellectual property protection and rare-disease regulatory pathways that may allow for accelerated approval. In the ongoing Phase 1/2 trial for LCA5, visual acuity improved and was maintained in the adult cohort over 24 months, with dosing for the pivotal Phase 3 trial expected to start in the fourth quarter of 2026.

For BEST1, dosing in the first cohort was completed in May 2026, with three-month topline data expected in September 2026. Two additional programs, OPGx-RDH12 and OPGx-MERTK, are scheduled to begin clinical testing in late 2026 and early 2027, respectively.

Opus Genetics, Inc. (NASDAQ:IRD) shares are up nearly 110% year-to-date as of July 2, 2026.

Opus Genetics, Inc. (NASDAQ:IRD) is engaged in the research and development of ophthalmic biopharmaceutical products, with a focus on developing and commercializing therapies for several eye disorders.

4. SAB Biotherapeutics, Inc. (NASDAQ:SABS)

Number of Hedge Fund Holders: 27

Upside Potential: 222.16%

SAB Biotherapeutics, Inc. (NASDAQ:SABS) ranks among the overlooked penny stocks to buy right now, supported by strong upside potential. Back-to-back bullish analyst calls are pointing to a wide gap between the company’s market value and the opportunity Wall Street sees in its lead diabetes program.

On June 24, 2026, Barclays analyst Eliana Merle initiated coverage of SAB Biotherapeutics, Inc. (NASDAQ:SABS) with an “Overweight” rating and a $13 price target.

Merle told investors the type 1 diabetes market is large and that SAB-142 could represent a significant opportunity as a potential disease modifying therapy. According to the firm, the next major catalyst for the stock is SAB’s Phase 2b data expected in the second half of 2027, while Tzield’s recent approval has reduced regulatory uncertainty surrounding SAB-142. Barclays argued that SAB Biotherapeutics, Inc. (NASDAQ:SABS)’s $300 million market capitalization fails to reflect the potential $4 billion market opportunity for SAB-142 in type 1 diabetes therapy.

That view followed a June 15, 2026 note from H.C. Wainwright analyst Emily Bodnar, who maintained a “Buy” rating on SAB Biotherapeutics, Inc. (NASDAQ:SABS) with a $10 price target.

Bodnar said Sanofi’s accelerated approval of Tzield in Stage 3 type 1 diabetes validates the use of C-peptide as a surrogate endpoint, reducing development risk for SAB-142’s ongoing SAFEGUARD trial. She also cited differentiation from Tzield and rabbit ATG on safety and immunogenicity, minimal immune-related toxicities in early data, and support for a twice-yearly maintenance regimen as reasons behind the firm’s positive risk-reward view on SAB Biotherapeutics, Inc. (NASDAQ:SABS).

SAB Biotherapeutics, Inc. (NASDAQ:SABS) is a clinical-stage biopharmaceutical company that focuses on the development of human polyclonal immunotherapeutic antibodies. Its main product candidate is SAB-142 for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.

3. Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX)

Number of Hedge Fund Holders: 20

Upside Potential: 275.72%

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. An expanding radiopharmaceutical pipeline, now stretching into a new brain tumor indication, is strengthening the company’s long-term growth narrative.

On July 1, 2026, Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) updated its corporate presentation to highlight progress across its 212Pb-based radiopharmaceutical pipeline and its integrated manufacturing strategy. The update emphasized the company’s theranostic approach targeting solid tumors with next-generation alpha therapies, along with plans to expand its addressable market through regional daily production and direct-to-hospital delivery. The presentation provided material related to multiple ongoing Phase 1/2a trials, including VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma, and PSV359 for FAP-α-expressing solid tumors, with early data pointing to deepening and durable responses, favorable safety and tolerability, and improved tumor retention.

That update followed news on June 3, 2026, that Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) dosed the first meningioma patient with [212Pb]VMT-α-NET in its ongoing Phase 1/2a study. The new cohort is designed to evaluate safety, dosimetry and preliminary anti-tumor activity in meningioma, expanding the company’s strategy of testing VMT-α-NET across somatostatin receptor subtype 2 (SSTR2)-expressing tumor types beyond neuroendocrine tumors. Meningiomas represent roughly 40% of primary central nervous system tumors diagnosed annually in the United States, and consistently express SSTR2, supporting their role as a target for this class of therapy.

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies (TATs) for cancer using the isotope Pb-212. Its theranostic approach combines imaging (Pb-203) with therapy (Pb-212) to deliver targeted radiation directly to tumors, minimizing damage to healthy tissue, with active trials for neuroendocrine tumors and melanoma.

2. Altimmune, Inc. (NASDAQ:ALT)

Number of Hedge Fund Holders: 23

Upside Potential: 392.06%

Altimmune, Inc. (NASDAQ:ALT), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. Fresh analyst confidence in the company’s MASH drug candidate follows strong data that continues to build the case for pemvidutide.

On June 22, 2026, Leerink analyst Thomas Smith initiated coverage of Altimmune, Inc. (NASDAQ:ALT) with an “Outperform” rating and a $10 price target. Smith called Altimmune an attractive play in a market for MASH therapeutics that is increasingly supported by clinical data, pointing to pemvidutide’s differentiated dual-agonist profile and its potential to expand into adjacent liver and alcohol-related indications.

That call followed 48-week results from the company’s IMPACT Phase 2b trial, announced in May, evaluating pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH). Altimmune, Inc. (NASDAQ:ALT) said the dual glucagon/GLP-1 receptor agonist significantly enhanced several cardiometabolic measures in comparison to placebo. Patients on the 1.8 mg dose saw notable improvements in triglycerides and total cholesterol, along with continued weight loss, lower body mass index, reduced waist circumference, and improvements in both systolic and diastolic blood pressure.

Presented at the European Association for the Study of the Liver Congress 2026 in Barcelona, the findings also suggested that pemvidutide was generally well tolerated over 48 weeks, with only a small proportion of patients not continuing treatment due to adverse events. Earlier data had already demonstrated notable improvements in liver fibrosis and liver stiffness in patients receiving pemvidutide compared with placebo.

Altimmune, Inc. (NASDAQ:ALT) is a clinical-stage biopharmaceutical company developing pemvidutide, a dual GLP-1/glucagon receptor agonist for metabolic and liver diseases.

1. Context Therapeutics Inc. (NASDAQ:CNTX)

Number of Hedge Fund Holders: 19

Upside Potential: 721.96%

Context Therapeutics Inc. (NASDAQ:CNTX) ranks among the overlooked penny stocks to buy right now, supported by strong upside potential. A sharp stock selloff tied to early clinical data has drawn a series of analysts defending the shares as oversold. The stock is down nearly 60% year-to-date.

On June 16, 2026, Maxim analyst Jason McCarthy lowered the firm’s price target on Context Therapeutics Inc. (NASDAQ:CNTX) to $4 from $8 while maintaining a “Buy” rating. The cut followed the company’s interim Phase 1a data for CTIM-76 in platinum-resistant ovarian cancer, but McCarthy called the sharp negative stock reaction an overreaction, noting the study remains exploratory and focused on learning about the drug’s pharmacokinetic (PK) profile, dosing, safety, and initial efficacy.

That view echoed commentary from a day earlier. On June 15, 2026, Jones Research called the selloff in Context Therapeutics Inc. (NASDAQ:CNTX) a buying opportunity, describing the Phase I update of CTIM-76 in CLDN6-positive solid tumors as encouraging. The firm pointed to a 29% overall response rate in platinum-resistant ovarian cancer patients who had a median of seven prior therapies, contrasting that with Zymeworks’ ZW191, tested in patients with a median of three prior therapies. Jones kept a “Buy” rating and $7 price target. Shares fell 47%, or 65 cents, to 74 cents that afternoon, TheFly reported.

On June 15, 2026, H.C. Wainwright analyst Emily Bodnar noted that CTIM-76 data indicated competitive activity versus peers despite a challenging patient population, while reiterating a “Buy” rating and $5 price target on Context Therapeutics Inc. (NASDAQ:CNTX).

Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors, including CTIM-76, CT-95, and CT-202, targeting CLDN6, MSLN, and Nectin-4 respectively.

READ NEXT: Top 10 Stocks to Buy for Financial Stability and 10 Stocks Under $20 That Will Explode.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.